Literature DB >> 18622260

Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke.

Lucia A Hindorff1, Rozenn N Lemaitre, Nicholas L Smith, Joshua C Bis, Kristin D Marciante, Kenneth M Rice, Thomas Lumley, Daniel A Enquobahrie, Guo Li, Susan R Heckbert, Bruce M Psaty.   

Abstract

OBJECTIVE: Genetic polymorphisms are associated with lipid-lowering response to statins, but generalizeability to disease endpoints is unclear. The association between 82 common single nucleotide polymorphisms (SNPs) in six lipid-related or statin-related genes (ABCB1, CETP, HMGCR, LDLR, LIPC, NOS3) and incident nonfatal myocardial infarction (MI) and ischemic stroke was analyzed according to current statin use and overall in a population-based case-control study (856 MI, 368 stroke, 2686 controls).
METHODS: Common SNPs were chosen from resequencing data using pairwise linkage disequilibrium. Gene-level analyses (testing global association within a gene) and SNP-level analyses (comparing the number of observed vs. expected associations across all genes) were performed using logistic regression, setting nominal statistical significance at P value of less than 0.05.
RESULTS: No gene-level interactions with statin use on MI or stroke were identified. Across all genes, two SNP-statin interactions on MI were observed (one ABCB1, one LIPC) and five interactions on stroke (one CETP, four LIPC). The strongest SNP-statin interaction was for synonymous CETP SNP rs5883 on stroke (P=0.008). Gene-level associations were present for LIPC and MI (P=0.026), but not other genes or outcomes. SNP-level associations included three SNPs with MI (one LDLR, two LIPC) and two SNPs with stroke (one CETP, one LDLR). The number of observed SNP associations was no greater than expected by chance.
CONCLUSION: Several potential novel associations or interactions of SNPs in ABCB1, CETP, LDLR, and LIPC with MI and stroke were identified; however, our results should be regarded as hypothesis generating until corroborated by other studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622260      PMCID: PMC2736793          DOI: 10.1097/FPC.0b013e3283033528

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  17 in total

Review 1.  The genetic basis of variability in drug responses.

Authors:  Dan M Roden; Alfred L George
Journal:  Nat Rev Drug Discov       Date:  2002-01       Impact factor: 84.694

2.  Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.

Authors:  Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson
Journal:  Am J Hum Genet       Date:  2003-12-15       Impact factor: 11.025

Review 3.  The role of haplotypes in candidate gene studies.

Authors:  Andrew G Clark
Journal:  Genet Epidemiol       Date:  2004-12       Impact factor: 2.135

4.  Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.

Authors:  S M Boekholdt; F M Sacks; J W Jukema; J Shepherd; D J Freeman; A D McMahon; F Cambien; V Nicaud; G J de Grooth; P J Talmud; S E Humphries; G J Miller; G Eiriksdottir; V Gudnason; H Kauma; S Kakko; M J Savolainen; M Arca; A Montali; S Liu; H J Lanz; A H Zwinderman; J A Kuivenhoven; J J P Kastelein
Journal:  Circulation       Date:  2005-01-17       Impact factor: 29.690

5.  Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women.

Authors:  B M Psaty; N L Smith; R N Lemaitre; H L Vos; S R Heckbert; A Z LaCroix; F R Rosendaal
Journal:  JAMA       Date:  2001-02-21       Impact factor: 56.272

6.  Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects.

Authors:  Marilu Fiegenbaum; Fabiano R da Silveira; Cézar R Van der Sand; Luiz Carlos Van der Sand; Maria E W Ferreira; Renan C Pires; Mara H Hutz
Journal:  Clin Chim Acta       Date:  2005-07-20       Impact factor: 3.786

7.  A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol.

Authors:  R Guerra; J Wang; S M Grundy; J C Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

Review 8.  Hepatic lipase: a marker for cardiovascular disease risk and response to therapy.

Authors:  Alberto Zambon; Samir S Deeb; Paolo Pauletto; Gaetano Crepaldi; John D Brunzell
Journal:  Curr Opin Lipidol       Date:  2003-04       Impact factor: 4.776

9.  Pharmacogenetic study of statin therapy and cholesterol reduction.

Authors:  Daniel I Chasman; David Posada; Lakshman Subrahmanyan; Nancy R Cook; Vincent P Stanton; Paul M Ridker
Journal:  JAMA       Date:  2004-06-16       Impact factor: 56.272

Review 10.  Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors.

Authors:  Anke Hilse Maitland-van der Zee; Olaf H Klungel; Bruno H Ch Stricker; W M Monique Verschuren; John J P Kastelein; Hubertus G M Leufkens; Anthonius de Boer
Journal:  Atherosclerosis       Date:  2002-08       Impact factor: 5.162

View more
  6 in total

1.  Association of apolipoprotein M gene polymorphisms with ischemic stroke in a Han Chinese population.

Authors:  Dongxue Zhao; Zhiyi He; Xue Qin; Lei Li; Fang Liu; Shumin Deng
Journal:  J Mol Neurosci       Date:  2010-09-25       Impact factor: 3.444

Review 2.  Cardiovascular pharmacogenomics: current status and future directions.

Authors:  Dan M Roden
Journal:  J Hum Genet       Date:  2015-07-16       Impact factor: 3.172

3.  Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients.

Authors:  Wai-Johnn Sam; Christine E Chamberlain; Su-Jun Lee; Joyce A Goldstein; Douglas A Hale; Roslyn B Mannon; Allan D Kirk; Yuen Yi Hon
Journal:  Transplantation       Date:  2012-11-15       Impact factor: 4.939

4.  Association of LIPC and advanced age-related macular degeneration.

Authors:  J Lee; J Zeng; G Hughes; Y Chen; S Grob; L Zhao; C Lee; M Krupa; J Quach; J Luo; J Zeng; X Wei; X Zhang; J Zhu; Y Duan; H Ferreyra; M Goldbaum; W Haw; P X Shaw; L Tang; K Zhang
Journal:  Eye (Lond)       Date:  2013-01-25       Impact factor: 3.775

Review 5.  Hypertension and aging.

Authors:  Thomas W Buford
Journal:  Ageing Res Rev       Date:  2016-02-01       Impact factor: 10.895

6.  Gene-drug interaction in stroke.

Authors:  Serena Amici; Maurizio Paciaroni; Giancarlo Agnelli; Valeria Caso
Journal:  Stroke Res Treat       Date:  2011-11-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.